You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
透視港股通丨內資拋售藥明生物

北水總結

12月15日港股市場,北水成交淨買入34.75億,其中港股通(滬)成交淨買入17.03億港元,港股通(深)成交淨買入17.72億港元。

北水淨買入最多的個股是騰訊(00700)、中芯國際(00981)、華潤電力(00836)。北水淨賣出最多的個股是藥明生物(02269)、長城汽車(02333)、信達生物(01801)。

數據來源:盈立智投APP

十大成交活躍股

數據來源:盈立智投APP

個股點評

北水資金繼續加倉科網股,騰訊(00700)分別獲淨買入7.5億、1.89億港元。消息面上,摩根大通全球股票研究主管Dubravko Lakos-Bujas在接受電視採訪時表示,市場正在定價一個激進的美聯儲,但他的同事們預計美聯儲將採取更平衡的方法來應對激增的通脹,以免扼殺增長。他指出,投資者應該重新考慮他們對科技巨頭的喜愛,並開始尋找風險資產,如被打壓的高成長型股票和中概股。

華潤電力(00836)獲淨買入3.26億港元。消息面上,中信證券指出,供需環境好轉可期,火電在2022年走出至暗時刻重新恢復盈利能力;系統成本上升推動以及電力市場機制完善,預計國內用電價格有望逆轉前期的降價趨勢而進入上漲週期。

青島啤酒股份(00168)獲淨買入1.95億港元。消息面上,高盛此前發表報告指,受疫情、成本壓力及更廣泛的消費行業向下重評影響,啤酒股股價年初至今下跌了15%。但該行認爲啤酒行業的高端化趨勢仍然穩健,在受疫情影響的過去兩年的年均複合增長率仍有9%至10%。預計行業未來將會維持雙位數增長、產品均價繼續上升及毛利率擴張。該行將青島啤酒評級由“中性”上調至“買入”目標價由84港元升至87港元。值得一提的是,青島啤酒股份公告稱,復星集團於12月9日減持公司H股3800萬股,本次權益變動後,復星集團持有公司股份比例由7.84%下降至5.06%。

碧桂園服務(06098)獲淨買入1.26億港元。消息面上,碧桂園服務公告稱,自公告日期起六個月內,集團與公司的關連人士碧桂園集團預計不會發生對價超過2億元人民幣(無論個別或合併)的重大資產出售或收購交易;不會在公開市場進行配售新股。此外,董事會獲悉,公司控股股東、非執行董事兼董事會主席楊惠妍承諾,自本公告日期起六個月內,其自身以及楊惠妍行使控制權的任何公司不會出售其已持有的公司股份。

康希諾生物-B(06185)獲淨買入1.18億港元。消息面上,Aerogen和康希諾生物宣佈,雙方就康希諾生物旗下重組型新型冠狀病毒疫苗Convidecia採用Aerogen專有振動式網孔氣霧劑給藥技術,實現全球首款吸入給藥新冠疫苗達成開發和商業供貨合作夥伴關係。此外,有媒體報道,目前康希諾正在開展針對奧密克戎變異株的新冠疫苗開發工作。一旦發現有逃逸疫苗保護力的突變株出現,可迅速研製生產出針對新病毒株的產品。

CXO概念股今日全線重挫,藥明生物(02269)、信達生物(01801)分別遭淨賣出9.74億、8379萬港元。唯有金斯瑞生物科技(01548)獲北水追捧,全天淨買入額達6090萬港元。

此外,中芯國際(00981)、建設銀行(00939)分別獲淨買入3.31億、3103萬港元。而長城汽車(02333)再遭淨賣出1.58億港元。

當日港股通淨買入和淨賣出排行榜

(港股通持股比例排行,交易所數據T+2日結)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account